BioNTech SE - ADR vs iShares 7-10 Year Treasury Bond ETF — how do they compare? BioNTech SE - ADR trades at $92.23 (market cap $23.31B), while iShares 7-10 Year Treasury Bond ETF trades at $92.9. The key difference: BioNTech SE - ADR is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| BNTX | IEF | |
|---|---|---|
Market Cap | $23.31B | — |
Sector | Health | — |
52-Week High | $119.34 | $97.99 |
52-Week Low | $83.89 | $92.76 |
Enterprise Value | $6.60B | — |
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $93.67, up 2.72% today, with a bullish technical signal and strong analyst support. The stock faces fundamental challenges, including declining COVID-19 vaccine revenue and negative profitability, but holds a robust cash position of $16.78 billion. Recent news highlights leadership changes and pipeline advancements in oncology, with a consensus price target of $121.00 implying significant upside potential.
Outlook: Long-term growth hinges on oncology pipeline success, but near-term risks from vaccine demand volatility and net losses persist. Investment opportunity lies in discounted valuation relative to cash and pipeline assets, though execution risks and competitive pressures require careful monitoring.
IEF (iShares 7-10 Year Treasury Bond ETF) trades at $93.17 with minimal daily movement (+0.24%). Technical indicators show a neutral to bearish bias with moving averages signaling caution. The ETF maintains consistent dividend distributions, with recent payments of $0.31-$0.32 per share. Market focus remains on Treasury yield movements influenced by inflation data and Middle East tensions affecting oil prices.
Outlook remains tied to interest rate expectations and inflation trends. Recent institutional accumulation by Bank of America and Ferguson Shapiro provides support, but rising Treasury yields pose headwinds. Key risks include Federal Reserve policy shifts and geopolitical volatility impacting bond markets.
Trailing returns across standard periods
Latest headlines on both assets
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →